PMID- 35141740
OWN - NLM
STAT- MEDLINE
DCOM- 20220225
LR  - 20220225
IS  - 2040-3372 (Electronic)
IS  - 2040-3364 (Linking)
VI  - 14
IP  - 8
DP  - 2022 Feb 24
TI  - Doxorubicin-loaded polypyrrole nanovesicles for suppressing tumor metastasis 
      through combining photothermotherapy and lymphatic system-targeted chemotherapy.
PG  - 3097-3111
LID - 10.1039/d2nr00186a [doi]
AB  - The lymphatic system provides a main route for the dissemination of most 
      malignancies, which was related to high mortality in cancer patients. Traditional 
      intravenous chemotherapy is of limited effectiveness on lymphatic metastasis due 
      to the difficulty in accessing the lymphatic system. Herein, a novel 
      lymphatic-targeting nanoplatform is prepared by loading doxorubicin (DOX) into 
      sub-50 nm polypyrrole nanovesicles (PPy NVs). The PPy NVs possessed hollow 
      spherical morphologies and a negative surface charge, leading to high drug 
      loading capacity. These vesicles can also convert near-infrared (NIR) light into 
      heat and thus can be used for tumor thermal ablation. DOX loaded PPy NVs (PPy@DOX 
      NVs) along with NIR illumination are highly effective against 4T1 breast cancer 
      cells in vitro. More importantly, following subcutaneous (SC) injection, a direct 
      lymphatic migration of PPy@DOX NVs is confirmed through fluorescence observation 
      of the isolated draining nodes. The acidic conditions in metastatic nodes might 
      subsequently trigger the release of the encapsulated DOX NVs based on their 
      pH-sensitive release profile. In a mouse model bearing 4T1 breast cancer, 
      lymphatic metastases, as well as lung metastases, are significantly inhibited by 
      nanocarrier-mediated trans-lymphatic drug delivery in combination with 
      photothermal ablation. In conclusion, this platform holds great potential in 
      impeding tumor growth and metastasis.
FAU - Wang, Lu
AU  - Wang L
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education 
      College of Bioengineering, Chongqing University, Chongqing 400044, China. 
      kaiyong_cai@cqu.edu.cn.
FAU - Liu, Genhua
AU  - Liu G
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education 
      College of Bioengineering, Chongqing University, Chongqing 400044, China. 
      kaiyong_cai@cqu.edu.cn.
FAU - Hu, Yunping
AU  - Hu Y
AD  - Fujian Provincial Key Laboratory of Advanced Materials Oriented Chemical 
      Engineering, College of Chemistry and Materials Science, Fujian Normal University 
      Fuzhou, Fujian 350007, China.
FAU - Gou, Shuangquan
AU  - Gou S
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education 
      College of Bioengineering, Chongqing University, Chongqing 400044, China. 
      kaiyong_cai@cqu.edu.cn.
FAU - He, Tingting
AU  - He T
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education 
      College of Bioengineering, Chongqing University, Chongqing 400044, China. 
      kaiyong_cai@cqu.edu.cn.
FAU - Feng, Qian
AU  - Feng Q
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education 
      College of Bioengineering, Chongqing University, Chongqing 400044, China. 
      kaiyong_cai@cqu.edu.cn.
FAU - Cai, Kaiyong
AU  - Cai K
AUID- ORCID: 0000-0001-9029-680X
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education 
      College of Bioengineering, Chongqing University, Chongqing 400044, China. 
      kaiyong_cai@cqu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220224
PL  - England
TA  - Nanoscale
JT  - Nanoscale
JID - 101525249
RN  - 0 (Polymers)
RN  - 0 (Pyrroles)
RN  - 30604-81-0 (polypyrrole)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Doxorubicin/pharmacology
MH  - Drug Liberation
MH  - Humans
MH  - *Lung Neoplasms
MH  - Lymphatic System
MH  - Mice
MH  - *Nanoparticles/therapeutic use
MH  - Polymers
MH  - Pyrroles
EDAT- 2022/02/11 06:00
MHDA- 2022/02/26 06:00
CRDT- 2022/02/10 05:41
PHST- 2022/02/11 06:00 [pubmed]
PHST- 2022/02/26 06:00 [medline]
PHST- 2022/02/10 05:41 [entrez]
AID - 10.1039/d2nr00186a [doi]
PST - epublish
SO  - Nanoscale. 2022 Feb 24;14(8):3097-3111. doi: 10.1039/d2nr00186a.